| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.40M | $24.41M | NEW |
| Citadel Ken Griffin | 2.79M | $19.97M | NEW |
| Point72 Steve Cohen | 686K | $4.92M | NEW |
| Marshall Wace | 440K | $3.15M | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK | 2026-08-05 | sale | $1k – $15k |
Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology, and chronic disease management. The company offers products such as contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, alongside a range of mature branded medicines for pain, respiratory conditions, and cardiovascular disorders. Organon & Co. operates across major geographies, with significant presence in Europe, Canada, the United States, Asia Pacific, and Japan. It emphasizes research and development to advance therapies in women’s health and biosimilars, while maintaining a strong lineup of established products that provide reliable treatment options worldwide. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. plays a vital role in the pharmaceutical sector by bridging innovation with accessible healthcare solutions for diverse patient populations.
Earnings calendar coming soon. Subscribe to get notified when OGN reports next.
Get earnings alerts →